Submit Deal

RENASANT BIO

HQ - Berkeley

Summary

Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 40 M

Avg. Deal Size£ 40 M

Market Context

Senior Management

Emily Conley
CEO
Rachel Gallagher
Vice President, Biology
Michelle Ho Huey
Vice President, Strategy and Operations

Sort

gus gustafson

CSO at RENASANT BIO

Manager

Deal

£ 40 M

Total Value

emily conley

CEO at RENASANT BIO

Manager

Deal

£ 40 M

Total Value

rachel gallagher

Vice President, Biology at RENASANT BIO

Manager

Deal

£ 40 M

Total Value

michelle ho huey

Vice President, Strategy and Operations at RENASANT BIO

Manager

Deal

£ 40 M

Total Value

b. barry toure

Senior Vice President, Drug Discovery at RENASANT BIO

Manager

Deal

£ 40 M

Total Value

natalie holles

Chair of the Board at RENASANT BIO

Manager

Deal

£ 40 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy